Vaginal Estrogen for Asymptomatic Microscopic Hematuria
Vaginal Estrogen for Asymptomatic Microscopic Hematuria
The specific aim of this protocol is to determine whether vaginal estrogen is an effective
 treatment for asymptomatic microscopic hematuria in postmenopausal women. The investigators
 hypothesize that women who use vaginal estrogen for three months will be more likely to have
 resolution of their asymptomatic microscopic hematuria compared with women who do not use
 vaginal estrogen.
This is a multi-center, randomized controlled trial to evaluate whether vaginal estrogen is
 an effective treatment for asymptomatic microscopic hematuria. Postmenopausal women with
 asymptomatic microscopic hematuria will be recruited from the two urogynecology clinics that
 serve as the clinic sites for the Mount Auburn Hospital/Beth Israel Deaconess Medical Center
 Female Pelvic Medicine and Reconstructive Surgery fellowship.

 Participants are eligible if they are postmenopausal, defined by amenorrhea for at least one
 year or a bilateral oophorectomy at least one year prior, and have three or more red blood
 cells per high powered field visible in a properly collected urine specimen without evidence
 of infection. In addition, participants must have a negative cystoscopy and computed
 tomography urogram (or magnetic resonance urography if history of renal insufficiency or
 contrast allergy) within the past three years. Exclusion criteria include any of the
 following: current or past thromboembolic disorder or cerebrovascular accident, intolerance
 to previous estrogen replacement therapy or hormone replacement therapy, estrogen dependent
 neoplasm within the past five years (unless supporting documentation from patient's
 oncologist is obtained), estrogen replacement therapy or hormone replacement therapy within
 the past three months or selective estrogen receptor modulators within eight weeks of
 enrollment, urinary tract infection, urinary calculi, urinary tract malignancy, vaginal
 bleeding of unknown origin, urethral caruncle, history of recurrent urinary tract infections
 in the last one year, and stage two or greater pelvic organ prolapse.

 Participants will be randomized to either an estradiol-releasing vaginal ring (Estring;
 Pfizer, New York, NY) or expectant management in a ratio of 1:1 using computer-generated
 block randomization stratified by enrollment site.

 Estring is a silicone vaginal ring, 5.5 cm in diameter, containing 2 mg of 17-estradiol,
 which is released at a rate of 7.5 g daily. The Estring was chosen as the vehicle for vaginal
 estrogen secondary to its ease of administration, higher patient preference, acceptability,
 and compliance.

 After eligibility is confirmed and written, informed consent is obtained, participants will
 be randomized to one of the two study arms. Participants randomized to the use of vaginal
 estrogen will have the vaginal ring placed by one of the investigators. Participants in both
 study arms will complete the short form of the Urogenital Distress Inventory (UDI-6) and the
 Incontinence Impact Questionnaire (IIQ-7).

 Participants in the vaginal estrogen arm will be called at two, four and eight weeks to
 ensure that the Estring is still in place and follow-up appointments will be scheduled as
 needed if there is any question as to whether the ring is still in place.

 At the 12-week visit all participants will provide a urine sample for urinalysis to assess
 whether the microscopic hematuria is present. All participants also will be asked to complete
 the UDI-6 and IIQ-7 and vaginal mucosal atrophy will be assessed as described above. Women in
 the vaginal estrogen arm will have the Estring removed and a new Estring will be placed by
 one of the investigators; participants also will be asked if the ring was removed or fell out
 during the past 12 weeks. All participants will be asked whether any of the following, (which
 could be a side effect from vaginal estrogen use) occurred in the previous 12 weeks:
 dyspareunia for subject or partner, vaginal bleeding, non-physiologic discharge, vaginal
 ulceration and vaginal irritation.

 participants will be followed for 24 weeks to determine if more than 12 weeks are needed for
 resolution.

 At the 24-week visit, all participants will provide a urine sample for urinalysis to assess
 whether the microscopic hematuria is present. All participants also will be asked to complete
 the UDI-6 and IIQ-7 and vaginal mucosal atrophy will be assessed as described above. We will
 ask all participants whether any of the following, which could be a side effect from vaginal
 estrogen use, occurred in the previous 12 weeks: dyspareunia for subject or their partner,
 vaginal bleeding, non-physiologic discharge, vaginal ulceration and vaginal irritation. One
 of the investigators will remove the Estring from all women in the vaginal estrogen arm.

 At the 24 week visit investigators will offer women in the expectant management arm with
 persistent microscopic hematuria the opportunity to try the Estring.
Inclusion Criteria:

 -  Postmenopausal, defined by amenorrhea for at least one year or a bilateral
 oophorectomy at least one year prior, and have three or more red blood cells per high
 powered field visible in a properly collected urine specimen without evidence of
 infection. In addition, women must have a negative cystoscopy and computed tomography
 urogram (or magnetic resonance urography if history of renal insufficiency or contrast
 allergy) within the past three years.

 Exclusion Criteria:

 -  Current or past thromboembolic disorder or cerebrovascular accident

 -  Intolerance to previous estrogen replacement therapy or hormone replacement therapy

 -  Estrogen dependent neoplasm within the past five years (unless supporting
 documentation from patient's oncologist is obtained)

 -  Estrogen replacement therapy or hormone replacement therapy within the past three
 months or selective estrogen receptor modulators within eight weeks of enrollment

 -  Urinary tract infection

 -  Urinary calculi

 -  Urinary tract malignancy

 -  Vaginal bleeding of unknown origin

 -  Urethral caruncle

 -  History of recurrent urinary tract infections in the last one year

 -  Stage two or greater pelvic organ prolapse.